Quantcast

Latest Priority Review Voucher Stories

2014-07-30 16:29:22

TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the Companies intend to use a U.S. Food and Drug Administration (FDA) rare pediatric disease priority review voucher in connection with the Biologics License Application (BLA) submission for alirocumab. The priority review voucher entitles the holder to designate a BLA for priority review, which provides for an expedited...

2008-08-26 09:00:28

VioQuest Pharmaceuticals (OTCBB: VOQP) today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta(TM) (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases. "Based on Lenocta's demonstrated...

2006-03-08 08:30:00

By Maggie Fox, Health and Science Correspondent WASHINGTON -- Companies that develop drugs to treat diseases of poor countries such as malaria should be rewarded with vouchers that might speed up government review of far more lucrative drugs, researchers proposed on Tuesday. Another set of researchers suggested that rich countries subsidize the use of the most effective drugs to fight malaria in poorer nations. Both reports, published in the journal Health Affairs, are aimed at finding ways...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related